Literature DB >> 9573000

Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients.

E Haddad1, P Landais, W Friedrich, B Gerritsen, M Cavazzana-Calvo, G Morgan, Y Bertrand, A Fasth, F Porta, A Cant, T Espanol, S Müller, P Veys, J Vossen, A Fischer.   

Abstract

We have performed a retrospective analysis of the development of T- and B-cell functions after HLA-nonidentical T-cell-depleted bone marrow transplantation (BMT) performed in 193 patients with severe combined immunodeficiency (SCID) at 18 European centers between December 1982 and December 31, 1993. One hundred sixteen of 193 patients were alive with evidence of engraftment 6 months after BMT. Development of T-cell function occurred earlier than B-cell function and was achieved more frequently up to the time of last follow-up. The median time to achieve normal T-cell function was 8.7 months, whereas the median time to achieve normal B-cell function was 14.9 months. Twenty-four patients died later than 6 months post-BMT, mainly due to chronic graft-versus-host disease (cGVHD) and/or viral infection. Absence of T-cell reconstitution 6 months after BMT, unlike absence of B-cell reconstitution, was associated with a poor outcome. Two additional factors were associated with a poor outcome: presence of cGVHD 6 months after BMT and B- SCID versus B+ SCID. However, two of these three factors remained as significant prognostic factors in a multivariate analysis: the absence of T-cell function and the presence of cGVHD 6 months after BMT. Analysis of the factors influencing the development of immune reconstitution showed that T- and B-cell functions occurred earlier and more frequently in B+ SCID versus B- SCID patients. Acute GVHD was associated with a slower development of T-cell function at 6 months, and cGVHD had a negative influence on the development of T-cell function afterwards, but neither acute nor chronic GVHD was found to influence the development of B-cell function. Once engraftment occurred, whether patients had or had not received Busulfan in the conditioning regimen did not influence the kinetics and quality of T-cell function development. In a multivariate study, two factors were found to influence the T-cell function 6 months after BMT: type of SCID and acute GVHD. The results of this retrospective analysis should lead to new protocols adapted to SCID disease, considering that disease-related as well as BMT-related parameters influence the development of immune function and thereby long-term outcome after HLA-nonidentical T-cell-depleted BMT.

Entities:  

Mesh:

Year:  1998        PMID: 9573000

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

Review 1.  Primary T-lymphocyte immunodeficiencies.

Authors:  A Fischer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

Review 2.  Severe combined immunodeficiencies (SCID).

Authors:  A Fischer
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 3.  Hematopoietic stem cell transplantation for severe combined immune deficiency.

Authors:  K I Weinberg; N Kapoor; A J Shah; G M Crooks; D B Kohn; R Parkman
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

Review 4.  Gene therapy of X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

5.  Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.

Authors:  Makoto Otsu; Masafumi Yamada; Satoru Nakajima; Miyuki Kida; Yoshihiro Maeyama; Norikazu Hatano; Nariaki Toita; Shunichiro Takezaki; Yuka Okura; Ryoji Kobayashi; Yoshinori Matsumoto; Osamu Tatsuzawa; Fumiko Tsuchida; Shunichi Kato; Masanari Kitagawa; Junichi Mineno; Michael S Hershfield; Pawan Bali; Fabio Candotti; Masafumi Onodera; Nobuaki Kawamura; Yukio Sakiyama; Tadashi Ariga
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

Review 6.  Survival of the fittest: in vivo selection and stem cell gene therapy.

Authors:  Tobias Neff; Brian C Beard; Hans-Peter Kiem
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

7.  Hematopoietic stem cell transplantation for CD3δ deficiency.

Authors:  Nufar Marcus; Hidetoshi Takada; Jason Law; Morton J Cowan; Juana Gil; Jose R Regueiro; Diego Plaza Lopez de Sabando; Eduardo Lopez-Granados; Jignesh Dalal; Wilhelm Friedrich; Hoenig Manfred; Imelda Celine Hanson; Eyal Grunebaum; William T Shearer; Chaim M Roifman
Journal:  J Allergy Clin Immunol       Date:  2011-07-16       Impact factor: 10.793

8.  Severe combined immunodeficiency: new advances in diagnosis and treatment.

Authors:  Jennifer M Puck
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

9.  Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment.

Authors:  Federica Cattaneo; Mike Recher; Stefania Masneri; Sachin N Baxi; Claudia Fiorini; Francesca Antonelli; Christian A Wysocki; Jose G Calderon; Hermann Eibel; Angela R Smith; Francisco A Bonilla; Erdyni Tsitsikov; Silvia Giliani; Luigi D Notarangelo; Sung-Yun Pai
Journal:  J Allergy Clin Immunol       Date:  2013-02-04       Impact factor: 10.793

10.  Matched unrelated bone marrow transplant for Omenn syndrome.

Authors:  Amit Nahum; Brenda Reid; Eyal Grunebaum; Chaim M Roifman
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.